胃癌合并幽门螺杆菌感染的临床治疗研究  

Clinical study on treatment of gastric cancer with Helicobacter pylori infection

作　　者：敬新蓉[1] 李青[1] 江恒[1] 孙薏[1] 

机构地区：[1]解放军452医院肿瘤科,成都610021

出　　处：《西南国防医药》2015年第2期126-129,共4页Medical Journal of National Defending Forces in Southwest China

基　　金：成都军区医学科技"十二五"重点项目(B12011)

摘　　要：目的探讨化疗与胃炎口服液联合常规质子泵抑制剂（PPI）三联疗法治疗胃癌合并幽门螺杆菌（Hp）感染的临床疗效及安全性。方法选择67例不能手术的Ⅲb～Ⅳ期胃癌合并Hp感染的患者,随机分为研究组和对照组,研究组35例,对照组32例。对照组给予常规化疗,研究组在常规化疗基础上,给予PPI三联疗法联用中药胃炎口服液治疗,比较两组的肿瘤临床疗效、Hp抑杀情况、患者的生活质量以及毒副反应。结果研究组肿瘤的疾病控制率（DCR）为74.29%,高于对照组的50.00%（P〈0.05）;研究组35例中,29例HP抑杀有效,Hp抑杀率为82.85%,这29例的肿瘤DCR为75.86%（22/29）,也显著高于对照组的DCR（50.00%,P〈0.05）。而Hp抑杀无效患者的DCR为66.67%（4/6）,与对照组DCR无显著差异（P〉0.05）。研究组恶心、呕吐、腹泻发生率高于对照组,但差异无统计学意义（P〉0.05）。结论中药胃炎口服液联合PPI三联疗法与化疗合用治疗Hp阳性的胃癌患者,能提高临床疗效,且安全有效。Objective To explore the clinical efficacy and safety of chemotherapy and Gastritis Oral Liquid combined with conventional proton pump inhibitor（PPI） based triple therapy on gastric cancer with Helicobacter pylori（Hp） infection. Methods Total 67 patients who suffered from stage-l~ b-IV gastric cancer complicated with Hb infection but could not receive the surgical operation were selected and randomly divided into a research group （n = 35 ）and a control group （n = 32）. The control group received conventional chemotherapy,on the basis of the conventional chemotherapy, the research group received PPI-based triple therapy with traditional Chinese medicine Gastritis Oral Liquid; and then, the clinical efficacy on the tumor, rate of killing Hp, life quality of patients, and side reactions were compared and analyzed between two groups. Results The tumor disease control rate（DCR） in the research group was 74.29% , higher than that in the control group （50.00%, P 〈 0.05 ） ;in 35 cases in the research group, Hp inhibition was effective in 29 cases ,with an inhibition rate of 82.85% and a tumor DCR of 75.86% （22/29） ,which was significantly higher than that in the control group（P 〈0.05） ,while the DCR of the patients on whom Hp inhibition was ineffective was 66.67% （4/6）, which had no significant difference tl＇om the control group（P 〉 0.05 ）. The incidences of nausea, vomiting, and diarrhea in the research group were higher than those in the control group, but the difference was not statistically significant （ P 〉 0.05 ）. Conclusion Chinese medicine Gastritis Oral Liquid combined with PPI-based triple therapy and chemotherapy in treatment of Hp positive gastric cancer patients can improve the clinical efficacy and is safe and effective.

关 键 词：胃癌 幽门螺杆菌 胃炎口服液 化疗 

分 类 号：R735.2[医药卫生—肿瘤]